ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

Date : June 19, 2017

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the European Cystic Fibrosis Society Conference, which took place between June 7th-10th in Seville. The study, which was conducted at Stanford University by Burgener and colleagues*, utilised the ProteaseTag® Active NE Immunoassay to associate Pf bacteriophage with higher levels of Pseudomonas aeruginosa and active neutrophil elastase in patients with CF.

At the same conference, the company presented data on the quantification of active neutrophil elastase (NE) using different sputum processing techniques. The study, with lead author Dr Charlene Robb, concluded that a basic sputum processing technique, which can be quickly and easily performed within a clinical setting, could be suitable for assessment of active NE, and may be combined with a rapid point-of-care test in the future, for quick clinical evaluation.

Dr David Ribeiro, CEO of ProAxsis, said: “It is very pleasing for the company to have expert centres utilising our ProteaseTag® Active NE Immunoassay in their ongoing research, especially when it is such a prestigious institution as Stanford. We’re delighted that our technology was beneficial to the important work they’re conducting”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact


*Burgener, E, Yacob, A, Bollyky, P and Milla, C (2017) Pf Bacteriophage (Pf) in Pseudomonas aeruginosa (Pa) biofilms is associated with increased elastase in the sputum of patients with cystic fibrosis (CF).